• SA46 Using Cloud Computing to Improve the Run-Time of Individual Patient Simulation Models

    Dec 1, 2022, 00:00

  • HPR193 Investigating the Correlation Between UK-Based Clinical Research and NICE Decision Making

    Dec 1, 2022, 00:00

  • HPR84 The Impact of Medical Incidents on Follow-up Medical Treatment Under Different Medical Insurance Systems

    Dec 1, 2022, 00:00

  • RWD58 Coding of Multiple Sclerosis Subtypes in German Administrative Claims Data: A Validation Study Using the MSDS-AOK PLUS Linked Database

    Dec 1, 2022, 00:00

  • PCR172 A Natural Language Processing (NLP) Approach to Automate Patients’ Testimonials Analysis

    Dec 1, 2022, 00:00

  • P56 Impact of Comorbidities on the Over-Mortality of People Living With Human Immunodeficiency Viruses (PLHIV)

    Dec 1, 2022, 00:00

  • MSR14 Developing an Abbreviated WHOQOL-BREF for Patients With Major Chronic Diseases Using the IRT Model

    Dec 1, 2022, 00:00

  • EE612 Healthcare Resource Utilization and Costs Among Patients With Chronic Obstructive Pulmonary Disease in the United States

    Dec 1, 2022, 00:00

  • RWD30 Cost of Asthma Hospitalizations in the Brazilian Public Health

    Dec 1, 2022, 00:00

  • PCR262 Real-World Outcomes and Health Care Resource Utilization of Onasemnogene Abeparvovec for US Patients With Spinal Muscular Atrophy Type 2: Results of a Retrospective Chart Review Study

    Dec 1, 2022, 00:00

  • EE200 A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs (NNIADS): Trends in Decision-Analytical Models (DAM) for Modelling of Type 2 Diabetes Mellitus (T2DM)

    Dec 1, 2022, 00:00

  • EE47 Micro-Costing of Hematopoietic Cell Transplantation, Graft-Versus-Host Disease and Veno-Occlusive Disease Associated with the Treatment of Acute Myeloid Leukemia in Argentina

    Dec 1, 2022, 00:00

  • EE298 Cost-Effectiveness of Brexucabtagene Autoleucel (Brexu-cel, CAR-T) for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma in Greece

    Dec 1, 2022, 00:00

  • HPR198 Faster, Simpler, and Easier: Analyzing the Reform of the French Early Access Pathway

    Dec 1, 2022, 00:00

  • P54 Antimicrobial Resistance Associated With Worse Outcomes in Hospitalized Adults With Pneumococcal Disease

    Dec 1, 2022, 00:00

  • PCR272 Attitudes Towards Coronavirus Vaccination Among the Hungarian Population

    Dec 1, 2022, 00:00

  • EPH67 Sleep Disorders, Depression, Anxiety, and Stress During the COVID-19 Pandemic

    Dec 1, 2022, 00:00

  • EE116 Budget Impact Analysis of a Combination Analgesic for the Management of the Acute Mild to Moderate Pain in Italy

    Dec 1, 2022, 00:00

  • CO143 Project Ideate: Creating a Novel Linked Real World Data Environment in Wales for Use in an Experimental, Retrospective Outcome-Based Agreement of a Breast Cancer Treatment

    Dec 1, 2022, 00:00

  • HSD79 Physicians’ Experience and Perceptions of Tetrabenazine for the Treatment of Tardive Dyskinesia

    Dec 1, 2022, 00:00

  • RWD149 Reduction in Ischemic Stroke Rates in Patients With Non-Valvular Atrial Fibrillation During the Period 2013-2020: A Real-Life Study in Spain

    Dec 1, 2022, 00:00

  • EE173 Cost-Effectiveness of Risdiplam for Patients with Types 1 - 3 Spinal Muscular Atrophy (SMA) in Francecost-Effectiveness of Risdiplam for Patients with Types 1 - 3 Spinal Muscular Atrophy (SMA) in France

    Dec 1, 2022, 00:00

  • EPH8 Factors Associated With Oral Anticoagulant Switching in Patients With Atrial Fibrillation

    Dec 1, 2022, 00:00

  • PCR119 Who We Are Matters: Inclusive Demographic Data Collection in Patient-Centered Outcomes Research

    Dec 1, 2022, 00:00

  • EE228 A Review of Treatment Effect Waning Methods for Immuno-Oncology Therapies in National Institute for Health and Care Excellence Technology Appraisals

    Dec 1, 2022, 00:00

  • EPH121 Future Trends of the COVID-19 Pandemics: What Should We Expect?

    Dec 1, 2022, 00:00

  • HTA140 Current Changes in Europe Impacting Orphan Drugs Access: A Focus on the Latest Reforms in the EU4 and England

    Dec 1, 2022, 00:00

  • EPH144 The Impact of COVID-19 Pandemic on the Detection and Management of Cancer: A German Claims Data Analysis

    Dec 1, 2022, 00:00

  • EE587 Cost-Effectiveness of Device-Based Long-Term Cardiac Monitoring in High-Risk Post-Myocardial Infarction Patients

    Dec 1, 2022, 00:00

  • EE302 Cost-Effectiveness of Nivolumab + Ipilimumab in First-Line Treatment of Unresectable Malignant Pleural Mesothelioma (uMPM) in the Netherlands

    Dec 1, 2022, 00:00

  • EE18 Systematic Literature Review of the Use of Productivity Losses/Gains in Cost-Effectiveness Analyses of Immune-Mediated Disorders

    Dec 1, 2022, 00:00

  • EE341 Economic Evaluations of Technologies for the Treatment of Rare Diseases in Latin America and Southeast Asia: A Scoping Review

    Dec 1, 2022, 00:00

  • EPH32 Investigation of the Correlations Between Premenstrual Syndrome, Physical Activity, Perceived Stress and Mental State Based on Cross-Sectional Research

    Dec 1, 2022, 00:00

  • EE197 Efficacy and Economic Impact of Metformin Plus Glibenclamide Treatment During the COVID-19 Pandemic in Ecuadorian Outpatients With Type II Diabetes Mellitus

    Dec 1, 2022, 00:00

  • HPR13 Impact of Income Shock on Health Care Utilization of Rural Residents in China - Evidence From CHARLS

    Dec 1, 2022, 00:00

  • EPH77 Prevalence of Common Chronic Diseases Among Overweight and Obese Adults in Greece

    Dec 1, 2022, 00:00

  • HPR22 Eight Years on, to What Extent Have Patients Benefitted from the UK's Early Access to Medicines Scheme (EAMS)?

    Dec 1, 2022, 00:00

  • HSD74 Hospitalization Costs of Motor Neurone Diseases (MND) in Germany

    Dec 1, 2022, 00:00

  • HTA93 The Impact of the EU-JCA Throughout European Healthcare Systems

    Dec 1, 2022, 00:00

  • RWD34 Comparison of ICU/Ventilator Usage Among Vaccinated and Unvaccinated COVID-19 Patients

    Dec 1, 2022, 00:00

  • HPR204 Role of Access-Reach Integration Framework (ARIF) in Optimizing Health Governance in Egypt – Health Policy Conceptual Paper

    Dec 1, 2022, 00:00

  • RWD6 Follicular Lymphoma: Epidemiology and Real-World Practices in France (EPICART Study)

    Dec 1, 2022, 00:00

  • OP4 Training Needs Assessment to Improve Regulatory Compliance and Professional Competency in the Pharmaceutical Industry

    Dec 1, 2022, 00:00

  • MSR87 Understanding Feline Pruritis From the Pet Owners Perspective: Can Social Media Listening Identify and Describe a Pet Patients Pathway Through a Disease Process in Veterinary Medicine?

    Dec 1, 2022, 00:00

  • HSD78 Systemic Amyloid Light Chain (AL) Amyloidosis Patient Experience Research

    Dec 1, 2022, 00:00

  • RWD106 Statistical Analysis Reproducibility Using Different Anonymization Techniques

    Dec 1, 2022, 00:00

  • EE45 Budget Impact Analysis of Introducing Amino Acid Formula to Infants With Cow's Milk Protein Allergy in Egypt

    Dec 1, 2022, 00:00

  • HPR176 Reimbursement of Antineoplastic and Immunomodulating Agents in Turkey: Comparison With Approvals of the FDA Between 2010-2021

    Dec 1, 2022, 00:00

  • RWD49 Bias Characterization of Real-World Patients With and Without Imaging in a Community Oncology Electronic Health Records Database

    Dec 1, 2022, 00:00

  • PCR274 One Universal Translation to Rule Them All...or Not?

    Dec 1, 2022, 00:00

  • CO11 Comparison of Relapse Rates in Ulcerative Colitis Patients With Mayo Endoscopic Score of 0 or 1: Systematic Literature Review and Meta-Analysis

    Dec 1, 2022, 00:00

  • RWD36 Comparison of True Versus Apparent Survival in Patients With Metastatic Non-Small Cell Cancer Treated in the Real-World Setting

    Dec 1, 2022, 00:00

  • CO52 Impact of Digital Interventions on Maintenance Treatment Adherence in Asthma: A Systematic Literature Review (SLR) and Meta-Analysis

    Dec 1, 2022, 00:00

  • EE33 Impact on Hospital Healthcare Resources, Comparison of Endoluminal Versus Surgical Treatment Strategies for Lower Limb Bypass in PAD Patients

    Dec 1, 2022, 00:00

  • PCR215 Quality of Life Study of Adult Population With Inflammatory Bowel Disease

    Dec 1, 2022, 00:00

  • HTA212 Real-Time Delphi Consultation on Medication Adherence Technologies: Consistency of Views Among Different Stakeholder Groups

    Dec 1, 2022, 00:00

  • MSR128 Swedish Nationwide Register Data as a Low-Cost Resource to Detect Drug-Repurposing Signals: A Study on De Novo Metastatic Breast Cancer Patients

    Dec 1, 2022, 00:00

  • EE81 The Budget Impact of Cangrelor for the Treatment of Patients Undergoing Percutaneous Coronary Intervention When Oral P2Y12 Inhibitors Are Not Feasible or Desirable in the UK

    Dec 1, 2022, 00:00

  • SA44 Meta-Analysis of Time-to-Event Oncology Outcomes for Health Economic Modelling

    Dec 1, 2022, 00:00

  • MSR135 Alternative Methods for Sampling Ordered Parameters in Probabilistic Sensitivity Analysis (PSA)

    Dec 1, 2022, 00:00

  • HTA179 Research on Assessment Mechanism of Online Diagnosis and Treatment Behavior in China

    Dec 1, 2022, 00:00

  • HTA13 How Health Technology Assessment Agencies View Clinical Evidence for Tumor Agnostic Therapies

    Dec 1, 2022, 00:00

  • CO92 Systematic Review of Currently Available Therapies for Crohn's Disease and Ulcerative Colitis

    Dec 1, 2022, 00:00

  • EE101 Comparison of Two French Cost-Effectiveness Opinions for the Same First-Line Treatment Combination in Renal Cell Carcinoma

    Dec 1, 2022, 00:00

  • CO176 Enriching Real World Evidence Insights Through QSAR Based Exposure Definitions

    Dec 1, 2022, 00:00

  • MSR89 Evaluating Prediction Model Calibration at the Moderate-Strong Level Using Patient Subgroups Identified With Clustering Analysis

    Dec 1, 2022, 00:00

  • EE595 Did We Follow the Right Approach in Economic Evaluations by Discounting Health Gain?

    Dec 1, 2022, 00:00

  • EE215 Pharmacoeconomic Analysis of Adjuvant Nivolumab for Patients With Resected Esophageal or Gastroesophageal Junction Cancer in Switzerland

    Dec 1, 2022, 00:00

  • EE181 Cost-Effectiveness of Single-Pill Combination Versus Free-Equivalent Combination in the Management of Hypertension

    Dec 1, 2022, 00:00

  • EE649 Contrasting 4 Different Mortality Predictions in Patients With Type 1 Diabetes Using the IQVIA Core Diabetes Model

    Dec 1, 2022, 00:00

  • EPH199 Epidemiology of Eye Disorders Due to the Use of Video Display Terminals in France, Germany, Italy, Spain and United Kingdom – A Systematic Literature Review

    Dec 1, 2022, 00:00

  • MSR122 Examining the Relationships and the Effects of Gender and Grade on Seven Widely Used Well-Being Scales

    Dec 1, 2022, 00:00

  • HPR168 Lessons Learned From NOACs and CV Drugs That Have Launched in the EU5, US, JP and BR? An HTA Review and Evidence Generation Standpoint

    Dec 1, 2022, 00:00

  • EE355 Budget Impact Model of a New rFVIIa (Eptacog Beta), for the On-Demand Treatment of Spontaneous Bleeding Events and Surgical Bleedings Among Hemophilia Patients with Inhibitors: A Payer Perspective From UK

    Dec 1, 2022, 00:00

  • MSR117 Are Classifiers the Future of Artificial Intelligence in Systematic Literature Reviews?

    Dec 1, 2022, 00:00

  • EE555 Direct Cost of Percutaneous Deep Vein Arterialization (PDVA) in an Italian Center

    Dec 1, 2022, 00:00

  • PCR266 Determinants of Emotional Distress Among Cancer Patients in Portugal: A Cross-Sectional Study

    Dec 1, 2022, 00:00

  • HPR171 COVID 19 Vaccination - How to Support Decisions on Vaccination Prioritization for New Variants of Concern?

    Dec 1, 2022, 00:00

  • EE43 Subcutaneous or Intravascular Route of Administration for Natalizumab in Relapsing Remitting Multiple Sclerosis: Economic Appraisal of the Easier Study

    Dec 1, 2022, 00:00

  • EE401 Cost-Effectiveness of OMNI® Surgical System Versus iStent Inject® for the Treatment of Primary Open-Angle Glaucoma in the United States

    Dec 1, 2022, 00:00

  • PCR250 Measuring Quality of Life of Patients With Age-Related Macular Degeneration in a Bulgarian Ophthalmic Clinic

    Dec 1, 2022, 00:00

  • MT27 Budget Impact of a Novel Digital Therapeutic for Amblyopia From a US Private Insurer Perspective

    Dec 1, 2022, 00:00

  • SA51 Different Ways to Present a DCE to Respondents: A Scoping Review

    Dec 1, 2022, 00:00

  • EE549 Hospital Care and Medical Costs of Septic Arthritis in Spain: A Retrospective Multicenter Analysis

    Dec 1, 2022, 00:00

  • EE237 Reimbursable Digital Healthcare Applications (DiGAs) in Germany: Price Developments and Payer Perspective

    Dec 1, 2022, 00:00

  • HPR211 China Drug Market Changes: How to Navigate the Future of Reimbursement in China?

    Dec 1, 2022, 00:00

  • P12 Addressing the Distributional Consequences of Spillovers in Health Economic Evaluation: A Prioritarian Approach

    Dec 1, 2022, 00:00

  • PCR86 Humanistic Burden of Informal Caregivers of Children and Young Adults With Newly Diagnosed Type 1 Diabetes (T1D): A Systematic Literature Review (SLR)

    Dec 1, 2022, 00:00

  • HSD114 Reductions in Travel Time and Carbon Dioxide Emissions Arising From Patient Transportation to Hospitals in England for Treatment With Intravenous Iron: An Analysis Comparing Ferric Derisomaltose With Ferric Carboxymaltose

    Dec 1, 2022, 00:00

  • EE484 Cost-Effectiveness Analysis of Sodium Zirconium Cyclosilicate for Treating Hyperkalemia Among Chinese Patients

    Dec 1, 2022, 00:00

  • MSR72 Collaborative, Multisectoral, and Multidisciplinary Approach to Enhance FDA One Health Initiative Communication Strategies

    Dec 1, 2022, 00:00

  • EPH62 Estimation of Patients With Psoriasis Potentially Eligible to Biologic Agents and Not Currently Treated With These Therapies: Analysis of Real-World Data in Italy

    Dec 1, 2022, 00:00

  • RWD119 Exploring the Relationship Between Prophylactic Infusion Frequency and Patient Utility for People With Haemophilia in Europe

    Dec 1, 2022, 00:00

  • SA27 Comparison of Comorbidity Indices Between Electronic Health Records (EHR) Derived Database and Claims Data Among Patients With Metastatic Breast Cancer

    Dec 1, 2022, 00:00

  • PCR157 The Impact of Single Pill Combination Versus Free Dose Equivalent on Outcomes in Patients With Hypertension and/or Dyslipidaemia: A Systematic Review

    Dec 1, 2022, 00:00

  • RWD113 Differences in Adverse Events Reporting Between Natural Products Versus Prescription Products in the United States and Canada

    Dec 1, 2022, 00:00

  • HPR136 The Associations of Prescription Drug Insurance and Cost-Sharing With Drug Use, Health Services Use, and Health – A Systematic Review of Canadian Studies

    Dec 1, 2022, 00:00

  • PCR207 Exploring and Addressing the Educational Needs of COPD Patients Through a Multinational Qualitative Survey Focused on Exacerbations: Results of the Romanian Cohort (Exacerbation Free)

    Dec 1, 2022, 00:00

  • PCR94 Difference in Health-Related Quality of Life Among People With and Without Disabilities

    Dec 1, 2022, 00:00

  • PCR180 Real-World Impact of Patient-Reported Outcome Measurement on Overall Survival and Healthcare Resource Utilization in Cancer Patients

    Dec 1, 2022, 00:00

  • HPR114 Is No Therapy a Therapy? Effects of Watchful Waiting as Appropriate Comparator Therapy for New Drugs on Benefit Assessment and Pricing in Germany

    Dec 1, 2022, 00:00

  • HPR130 Comparison of Diagnosis-Based Risk Adjustment Models for Episode-Based Cost

    Dec 1, 2022, 00:00

  • P6 EMA/EUnetHTA Qualification of the IMI PREFER Patient Preference Framework and Points to Consider for Method Selection: Key Experiences, Outcomes, Value and Implications

    Dec 1, 2022, 00:00

  • RWD87 Association Between Functional Endpoints and Quality-of-Life Outcomes in Huntington's Disease Gene Carriers: Results From a Real-World Data Analysis of the Enroll-HD Global Registry

    Dec 1, 2022, 00:00

  • EE194 Modelling Long-Term Clinical Outcomes of Patients With Sickle Cell Disease With Recurrent Vaso-Occlusive Crises in the United States

    Dec 1, 2022, 00:00

  • EPH185 Increased Influenza Vaccine Coverage Rate Following COVID-19: Durable Trend or Epiphenomenon?

    Dec 1, 2022, 00:00

  • EE88 Impact of Rational Use of Palivizumab in the Treatment of RSV in a Private Health Insurance Company in Brazil

    Dec 1, 2022, 00:00

  • EPH202 Use of National Healthcare Information Databases to Assess Sex Differences in Patient Care in Spain: The Case of Asthma (2017-2020)

    Dec 1, 2022, 00:00

  • RWD168 ER Visits, Procedures Conducted, and Associated Cost

    Dec 1, 2022, 00:00

  • HPR122 Cost-Based vs Value-Based - How Do Japan's and Germany's Pricing Frameworks Compare?

    Dec 1, 2022, 00:00

  • EE391 Impact of the COVID-19 Pandemic on the Healthcare Resource Use of People With Newly Diagnosed Mood/Affective Disorder

    Dec 1, 2022, 00:00

  • RWD118 Characterisation of Surgical Aortic Valve Replacements for Aortic Regurgitation in Spain During 2016-2019

    Dec 1, 2022, 00:00

  • SA34 Identifying References in a Literature Review Update: A Study Exploring Three Alternative Approaches

    Dec 1, 2022, 00:00

  • HTA139 Swedish Health Technology Assessment Outcomes and Considerations for Advanced Therapy Medicinal Products

    Dec 1, 2022, 00:00

  • SA43 Rapid Evidence Publication in the COVID-19 Era: Impact on Study Quality and Study Identification

    Dec 1, 2022, 00:00

  • EE42 The Societal Burden of Seasonal Influenza on Working-Aged Adults in The United Kingdom: Results From an Online Survey of The General Public

    Dec 1, 2022, 00:00

  • HTA251 Determining Factors of Simplified Evaluations in Norwegian Health Technology Assessments

    Dec 1, 2022, 00:00

  • HTA82 Health Technology Assessment of Hospital Medicines in Denmark: A Review of DMC Decisions (2017-2022)

    Dec 1, 2022, 00:00

  • EE419 Economic Evaluation of Extracorporeal Membrane Oxygenation (ECMO) vs Invasive Ventilation for COVID-19 Patients with Severe Acute Respiratory Distress Syndrome (ARDS)

    Dec 1, 2022, 00:00

  • HPR165 Defining a Global Disease Budget for HIV in Greece

    Dec 1, 2022, 00:00

  • EE617 Cost-Effectiveness of Meningococcal B Vaccination in the Netherlands

    Dec 1, 2022, 00:00

  • HPR135 Are Managed Entry Agreements a Feasible Approach to Improve Patient Access to Innovative Therapies in Latin America?

    Dec 1, 2022, 00:00

  • HPR26 Anti-PD(L)1: Does the Cost of Treatment Have an Impact on the Therapeutic Decision-Making?

    Dec 1, 2022, 00:00

  • HPR181 Towards Understanding the Value of Consequences in the Context of Watch-and-Wait Versus Surgery for People With Rectal Cancer Achieving Clinical Complete Response

    Dec 1, 2022, 00:00

  • MSR49 Comparison of Methods for Identifying Genome Profiling Actionability Prognostic Factors in the Context of Small Samples Using a RWD Study

    Dec 1, 2022, 00:00

  • HSD64 Drug Discontinuation and Healthcare Cost Evaluation in Crohn's Disease Patients Under Biologic Therapy: An Italian Retrospective Analysis

    Dec 1, 2022, 00:00

  • P66 Understanding of Post-COVID Conditions (PCC) and Related Burden of Illness

    Dec 1, 2022, 00:00

  • RWD88 Examining the Fitness-for-Purpose of European Real-World Data Sources for External Comparators in Haematological Malignancies

    Dec 1, 2022, 00:00

  • HSD9 Comparing the Quality of the Irish Healthcare System Versus the Healthcare Systems of the Nordic Countries Using Health Outcomes Data

    Dec 1, 2022, 00:00

  • EE395 A Cost-Utility Analysis of Ferric Derisomaltose Versus Ferric Carboxymaltose in Patients With Inflammatory Bowel Disease in the United Kingdom

    Dec 1, 2022, 00:00

  • EE567 Environmental Impact and Sustainability of Surgical Sets: The 4S Approach

    Dec 1, 2022, 00:00

  • HPR29 Assessing the Feasibility of Implementing Indication-Based Pricing in Sweden: A Qualitative Analysis

    Dec 1, 2022, 00:00

  • RWD41 Colorectal Cancer Screening Program Saved More Life Expectancy in Females and More Employment Duration in Males: Empirical Evidence From Analyzing Nationwide Data Followed for 15 Years in Taiwan

    Dec 1, 2022, 00:00

  • RWD135 Cost of Care of Elderly (65 Years and Above)

    Dec 1, 2022, 00:00

  • HPR183 Could Netflix Based Subscription Models Tackle the Shrinking Antibiotic Pipeline?

    Dec 1, 2022, 00:00

  • PCR213 Rehabilitation After Hip Replacement Surgery in the State and Private Health Care in Hungary

    Dec 1, 2022, 00:00

  • RWD68 Characteristics/Comorbidities of Vaccinated and Unvaccinated Patients With COVID-19

    Dec 1, 2022, 00:00

  • HTA138 Association of NCPE Submission Outcomes in Ireland With Additional Benefit Ratings in Germany

    Dec 1, 2022, 00:00

  • MSR42 Adoption of Artificial Intelligence in Systematic Reviews

    Dec 1, 2022, 00:00

  • EPH129 Hospitalizations for Chemotherapy-Induced Febrile Neutropenia in Patients With Lung Cancer in France From 2017 to 2020

    Dec 1, 2022, 00:00

  • PCR259 Factors Influencing Crowdfunding Donations for Patients With Dementia

    Dec 1, 2022, 00:00

  • EE318 Evaluating the Cost Effectiveness of the Towards Home-Based Albuminuria Screening (THOMAS) Study for Early Detection and Treatment of Chronic Kidney Disease

    Dec 1, 2022, 00:00

  • HTA158 A Comparison of HTA Economic Results in Ireland: The Applicant and Assessor Perspectives

    Dec 1, 2022, 00:00

  • EE296 Cost-Effectiveness of Faricimab in Patients With Neovascular Age-Related Macular Degeneration in Canada

    Dec 1, 2022, 00:00

  • CO54 Dupilumab vs Placebo Improves Symptoms, Asthma Control, and Asthma-Related Quality of Life in Patients With Oral Corticosteroid-Dependent Severe Asthma Through 48 Weeks of Follow up

    Dec 1, 2022, 00:00

  • RWD20 Changes in Clinical and Pathological Characteristics of Newly Diagnosed Breast Cancer Patients in Hungary: A 10-Year Retrospective Analysis

    Dec 1, 2022, 00:00

  • EPH26 Three-Year Epidemiology, Economic Burden and All-Cause Mortality Among Generalized Pustular Psoriasis Patients: A Canadian Incidence Study of Inpatient Care, Emergency Departments, and Hospital- or Community-Based Outpatient Clinics

    Dec 1, 2022, 00:00

  • PCR82 Association between Myasthenia Gravis-Activities of Daily Living (MG-ADL) and Eq-5D-5L Utility Values: The Additional Effect of Efgartigimod on Utilities

    Dec 1, 2022, 00:00

  • PCR150 Physicians’ Perceptions of the Impact of COVID-19 on Patient Access and Adherence

    Dec 1, 2022, 00:00

  • SA52 Indirect Comparison of Short-, Mid-, and Long-Term Efficacy of Treatments for Moderate to Severe Plaque Psoriasis: A Systemic Review and Network Meta-Analysis

    Dec 1, 2022, 00:00

  • HSD10 Medical Cannabis Legalization and Opioid- and Pain- Related Outcomes Among U.S. Patients Newly Diagnosed With Cancer and Receiving Anti-Cancer Treatment

    Dec 1, 2022, 00:00

  • EE573 Evaluating the Economic Burden of Metastatic Urothelial Carcinoma (mUC): A Real-World Analysis Using Hungarian Claims Data

    Dec 1, 2022, 00:00

  • HSD81 European Delphi Panel to Build Consensus on Tapering and Discontinuation of Thromboprotein-Receptor Agonists in Patients With Immune Thrombocytopenia

    Dec 1, 2022, 00:00

  • A Qualitative Investigation of Older Adults’ Conceptualization of Quality of Life and a Think-Aloud Content Validation of the EQ-5D-5L, SF-12v2, Warwick Edinburgh Mental Wellbeing Scale, and Office of National Statistics-4.

    Dec 1, 2022, 00:00

  • MT7 Artificial Intelligence Applied to Motor Activities: A Rapid Review of the Literature

    Dec 1, 2022, 00:00

  • EPH155 A Systematic Review of the Impact of Vaccination on Long COVID

    Dec 1, 2022, 00:00

  • EE314 Economic Impact of Feno Testing on the Italian Population With Asthma

    Dec 1, 2022, 00:00

  • EE38 Cost-Minimization Analysis of Damoctocog Alfa Pegol With the Treatment of Hemophilia A in Turkey

    Dec 1, 2022, 00:00

  • HPR11 Could DiGA be a Role-Model for a New Digital Health Process in the UK?

    Dec 1, 2022, 00:00

  • HPR175 Is International Reference Pricing Applied Consistently at Pharmaceutical Price Re-Evaluation for Retail and Specialty Products?

    Dec 1, 2022, 00:00

  • EPH16 Antidiabetic Drugs and the Incidence of Parkinson's Disease in Patients With Type 2 Diabetes: A Case-Control Study

    Dec 1, 2022, 00:00

  • HSD27 Constrained Optimization Model to Estimate Best Booster Allocation Strategy to Minimize Hospital Bed-Days Under a Fixed Healthcare Budget

    Dec 1, 2022, 00:00

  • EE596 Comparative Evaluation of the Health Utilities Index Mark 3 and the Short Form-6D: Evidence From an Individual Participant Data Meta-Analysis of Very Preterm and Very Low Birthweight Adults

    Dec 1, 2022, 00:00

  • P50 Methods to Acknowledge Patient Heterogeneity in Economic Evaluation: A Review of the Methods Literature

    Dec 1, 2022, 00:00

  • HTA197 What Drives the Limited Scope of French National Authority for Health (HAS) Economic Opinions for Rare Diseases in France?

    Dec 1, 2022, 00:00

  • HPR132 Budget Cap With Pay Back As Managed Entry Agreement Policy: Bulgarian Example for Rheumatology Medicines

    Dec 1, 2022, 00:00

  • EE489 The Cost of Treatment with Dupilumab in Severe Asthma Patients With Coexisting Other Type 2 Inflammatory Diseases

    Dec 1, 2022, 00:00

  • HSD44 The Concentration of Missed Appointments Within a Medicaid Accountable Care Organization

    Dec 1, 2022, 00:00

  • HPR88 Burden and Cost of Rotator Cuff Repair Surgery and Reimbursement of Its Treatment in a Developing Country: An Observational Study in Indonesia

    Dec 1, 2022, 00:00

  • EE30 An Economic Evaluation of Direct Oral Anticoagulants for Venous Thromboembolism in Thailand

    Dec 1, 2022, 00:00

  • PCR197 Psychometric Evaluation of a New Electronic Pediatric Asthma Symptom Diary

    Dec 1, 2022, 00:00

  • PCR81 Patient-Centered Benefit-Risk Assessment of a Novel Therapy for Alopecia Areata

    Dec 1, 2022, 00:00

  • MT34 The Dynamic and Context-Specific Value of a Medical Test - A Health Economic Perspective

    Dec 1, 2022, 00:00

  • EE447 Budget Impact Analysis of Tepotinib in England for Patients With Advanced Non-Small Cell Lung Cancer (aNSCLC) Harboring MET Exon 14 (METex14) Skipping

    Dec 1, 2022, 00:00

  • HPR6 Analysis of Patient Access to Personalized Oncology Medicines in Turkiye

    Dec 1, 2022, 00:00

  • EE365 Cost-Minimization and Budget Impact Analysis of Venetoclax Plus Obinutuzumab Compared With Acalabrutinib in the First Line and R/R Chronic Lymphocytic Leukemia From the Brazilian Private Healthcare Perspective

    Dec 1, 2022, 00:00

  • HTA200 Do Pharmacoeconomic Analyses Impact Price Negotiation Outcomes in Canada? Comparison of Rare Disease and Oncology Drugs

    Dec 1, 2022, 00:00

  • EPH1 Impact of YAG Laser Capsulotomy Procedures on Cataract Center Chair Time and Revenue Opportunity- A Cost Consequence Analysis at a Private Facility in India

    Dec 1, 2022, 00:00

  • EE93 Economic Consequences of the Implementation of HPV Screening in Bulgaria

    Dec 1, 2022, 00:00

  • EE482 Costs of Proton Therapy During the Start-up Phase Using Time-Driven Activity-Based Costing in the Netherlands

    Dec 1, 2022, 00:00

  • HPR2 Criteria to Define Rare Diseases and Orphan Drugs Systematic Literature Review

    Dec 1, 2022, 00:00

  • RWD12 Medication Adherence and Quality of Life of Patients With Multiple Sclerosis in Bulgaria - A Pilot Study

    Dec 1, 2022, 00:00

  • HTA68 Digital Health – Where Do We Stand From a Market Access Perspective in the EU-4 and the UK?

    Dec 1, 2022, 00:00

  • HSD77 Evaluation of a Transitional Care Strategy Implemented in Hospitalized Adults With High-Risk and Multimorbidity in Chile

    Dec 1, 2022, 00:00

  • HTA176 A Systematic Literature Review of Rationale, Methods, and Use of Cost-Effectiveness Thresholds in Health Technology Assessments

    Dec 1, 2022, 00:00

  • PCR126 Patient-Reported Experience With Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea – Results From a Pilot Study in Germany

    Dec 1, 2022, 00:00

  • PCR267 Evaluating Patient-Reported Experience Along the Inflammatory Bowel Disease Patient Journey in Portugal

    Dec 1, 2022, 00:00

  • HPR3 Country Score Tool for Readiness Assessment and Evidence Generation of Immunization Programs in Ageing Adults in Europe

    Dec 1, 2022, 00:00

  • HTA173 Productivity Losses in Pharmacoeconomic Guidelines in Europe and Asia: A Qualitative Review of Guidelines

    Dec 1, 2022, 00:00

  • CO149 Epidemiology and Burden of Oral Complications Following Breast Cancer Treatment - A Systematic Literature Review (PROSPERO CRD42021272130) - Mucositis and Stomatitis Incidence From Randomized Trials

    Dec 1, 2022, 00:00

  • HPR96 Trends in European Pharmaceutical Tender Requirements and Opportunities for Differentiation for Biosimilars

    Dec 1, 2022, 00:00

  • PCR245 'Please Complete Your Surveys:' A Targeted Review of Adherence Rates in Real-World Studies Using Digital Technologies

    Dec 1, 2022, 00:00

  • PCR113 Are Patient and General Population Samples Fundamentally Different? An Exploration Using a Discrete Choice Experiment (DCE)

    Dec 1, 2022, 00:00

  • EE238 Protocol for an EQ-5D-5L Elicitation Study Regarding Health State Valuations for Surviving Patients at Intensive Care Units

    Dec 1, 2022, 00:00

  • EE641 Economic and Health-Related Quality of Life Consequences of Imaging and Surveillance Schedule in Seminoma Testis

    Dec 1, 2022, 00:00

  • HSD22 Wet Age-Related Macular Degeneration: Trends in Real-World Treatment Patterns in the United States

    Dec 1, 2022, 00:00

  • PCR221 Health-Related Quality of Life Among Working Nurses in Hong Kong: The Role of Resilience Under the COVID-19 Pandemic

    Dec 1, 2022, 00:00

  • EPH6 Non-Muscle-Invasive Bladder Cancer: A Review of Burden and Unmet Need

    Dec 1, 2022, 00:00

  • SA3 Effect of Mortality on Cost-Effectiveness Modeling of Disease-Modifying Treatment for Alzheimer's Disease

    Dec 1, 2022, 00:00

  • MSR32 COVID-19 Beds’ Occupancy and Hospital Complaints: A Predictive Model

    Dec 1, 2022, 00:00

  • PCR174 Valuation of the EQ-5D-3L in Jordan

    Dec 1, 2022, 00:00

  • HTA11 U.S. Commercial Payer and Rare Disease Patient Stakeholder Perceptions of Value of Orphan Drugs

    Dec 1, 2022, 00:00

  • Natural Language Processing for Automated Classification of Qualitative Data From Interviews of Patients With Cancer

    Dec 1, 2022, 00:00

  • HPR41 Project Orbis to Accelerate Patient Access to Innovative Cancer Therapies: A Narrative Review

    Dec 1, 2022, 00:00

  • EPH7 A Survey of the Occurrence and Transmission of COVID-19 in Outdoor Education Settings in Canada

    Dec 1, 2022, 00:00

  • EPH19 Long Term Epidemiological Impact of Adjuvant Atezolizumab in Preventing the Recurrence of Early PDL1 High Non-Small Cell Lung Cancer in Europe

    Dec 1, 2022, 00:00

  • SA74 'How Easily Could You Obtain Proof of Diagnosis for Your Medical Condition?' Feedback From Individuals With Chronic Medical Conditions on a Digital Diagnosis Validation Feature

    Dec 1, 2022, 00:00

  • OP6 Quantifying the Impact of Persistent Musculoskeletal Pain on Employees at Rolls-Roy A Cross-Sectional Survey

    Dec 1, 2022, 00:00

  • PCR142 Adaptation of the Urticaria Patient Daily Diary for Caregiver Completion in Pediatric Chronic Spontaneous Urticaria

    Dec 1, 2022, 00:00

  • EE512 Comparing Costs of Immune Checkpoint Inhibitors for Treatment of 1L NSCLC in Colombia – A Cost Minimisation Analysis

    Dec 1, 2022, 00:00

  • EE54 Haemophilia Lifetime Cost Comparison for Austria: Annual Drug Costs in Comparison With Projected Gene Therapy Costs

    Dec 1, 2022, 00:00

  • HTA228 Willingness to Pay for Different Severity Levels in Sweden: An Analysis of TLV Decisions (2014-2022)

    Dec 1, 2022, 00:00

  • EE231 Use of Biomarkers in Health Care: What Health Economic Methods Are Used to Evaluate Them?

    Dec 1, 2022, 00:00

  • HSD111 Evaluation of the Implementation of Value-Based Healthcare With a Weekly Digital Follow-up of Lung Cancer Patients in Clinical Practice

    Dec 1, 2022, 00:00

  • EPH36 Taking a Bite Out of Claims Data to Provide Insights into Rare Events: A Descriptive Analysis of Shark, Pig, and Raccoon Bite Patients in the U.S.

    Dec 1, 2022, 00:00

  • HTA168 Data Maturity and Treatment Positioning to Support Reimbursement: The Case for Siltuximab (SYLVANT®) in Australia

    Dec 1, 2022, 00:00

  • PCR249 Responder Analysis of the Patient Life Interference Questionnaire in Children With Growth Hormone (GH) Deficiency Treated With Either Injections of Once Weekly GH (Somatrogon) or Once Daily GH (Genotropin) in a Phase 3 Trial

    Dec 1, 2022, 00:00

  • HSD54 Value-Based Healthcare (VBH): Application of Time-Driven-Activity-Based Costing (TDABC) Methodology in an Ophthalmic Clinic for Patients With Macular Degeneration (MD)

    Dec 1, 2022, 00:00

  • EE199 Impact on Healthcare Resource Utilization and Indirect Costs Among Individuals With Migraine and Preventive Treatment Failure in France, Germany, Italy, Spain and United Kingdom

    Dec 1, 2022, 00:00

  • RWD28 Cervical Cancer Screening Trend and Disparity in the US, 2016 – 2020

    Dec 1, 2022, 00:00

  • HPR137 Resource Utilization Trends Related With Precision Oncology in Chile

    Dec 1, 2022, 00:00

  • EE352 New Reimbursement Policy on Costly Treatments for Rehabilitation Care in Fran Estimated Impact in a University Hospital

    Dec 1, 2022, 00:00

  • EE467 A Review of the Use of Clinical Expert Opinion to Inform Survival Curve Extrapolations in Single Technology Appraisals of New Cancer Drugs by NICE, UK

    Dec 1, 2022, 00:00

  • MT25 Mobile Health Interventions in Mental Health Conditions: A Review on Development So Far and Gaps to Be Bridged

    Dec 1, 2022, 00:00

  • EE65 Budget Impact of Zanubrutinib for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia in the United States

    Dec 1, 2022, 00:00

  • MT30 A Systematic Review of Clinical and Economic Literature of Breast Cancer Screening with Digital Breast Tomosynthesis (DBT) Combined With Synthesised Two-Dimensional Mammography (S2D) Versus Digital Mammography Alone (DM)

    Dec 1, 2022, 00:00

  • PCR234 Patient Preference in Cervical Cancer Screening

    Dec 1, 2022, 00:00

  • PCR133 Subjective Financial Toxicity and Health-Related Quality of Life in Cancer Patients and Survivors: A Systematic Review and Meta-Analysis

    Dec 1, 2022, 00:00

  • EE177 A Budget Impact Analysis of a Novel Diagnostic Test to Differentiate Viral/Bacterial Etiology for Community-Acquired Pneumonia Patients Presenting to the Emergency Departments in Italy

    Dec 1, 2022, 00:00

  • Preference Variation: Where Does Health Risk Attitude Come Into the Equation? [Editor's Choice]

    Dec 1, 2022, 00:00

  • PCR277 Nutritional Status Assessment in Patients With Lung Cancer

    Dec 1, 2022, 00:00

  • PCR183 Does the Format of Educational Materials Impact Diabetes Patient Preferences for Glucose Monitoring Technology: A Randomized Study in Two Countries

    Dec 1, 2022, 00:00

  • HTA23 Restrictions and Real-World Evidence Requirements in the Health Technology Assessment of Gene Therapy Medicinal Products in Europe, Canada, Australia, and the United States

    Dec 1, 2022, 00:00

  • P3 How Much Did the COVID-19 Shielding Policy Cost in Wales? Results of a Cost Analysis Within the EVITE Immunity Evaluation

    Dec 1, 2022, 00:00

  • EE651 Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy in the First-Line Treatment of Patients With Metastatic Triple-Negative Breast Cancer in Greece

    Dec 1, 2022, 00:00

  • RWD13 Real World Criteria Used to Diagnose Relapsed/Refractory Status of Patients With Multiple Myeloma in Germany

    Dec 1, 2022, 00:00

  • EPH72 Relationship Between the Number of Approved Cancer Treatments and Unmet Need in Europe

    Dec 1, 2022, 00:00

  • EPH98 An Approach to Gender Disparities Through the Evaluation of Sex Differences in Hospital Diagnoses in Spain 2016-2020

    Dec 1, 2022, 00:00

  • EE654 Budget Impact Analysis of Bimekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis in Greece

    Dec 1, 2022, 00:00

  • PCR275 Patient Experience With Anti–Vascular Endothelial Growth Factor (VEGF) Therapy in Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME): A Multinational Survey

    Dec 1, 2022, 00:00

  • EE479 Economic and Humanistic Burden of Visual Impairment and Blindness in Brazil: A Grey Literature Review

    Dec 1, 2022, 00:00

  • RWD7 Need for Real-World Evidence in Consumer Health Setting and Its Potential Benefits

    Dec 1, 2022, 00:00

  • HSD69 Cost Savings of Waste on Health by Pharmacological Inefficiencies in a Value-Based Patient Drug Safety Program

    Dec 1, 2022, 00:00

  • CO166 Clinical Outcomes of Patients With Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion Cancer Treated With Non-Tropomyosin Recepter Kinase Inhibitors: A Systematic Literature Review

    Dec 1, 2022, 00:00

  • HPR74 International Reference Pricing Analysis of Medicines in Turkiye By 2021

    Dec 1, 2022, 00:00

  • EE96 Budget-Impact Analysis of Adopting Expanded Hemodialysis (HDX) Via Theranova® in Korea

    Dec 1, 2022, 00:00

  • EE157 Cost-Utility of Active Middle Ear Implants for Sensorineural Hearing Loss

    Dec 1, 2022, 00:00

  • MT2 Rate of Complete Spectacle Independence With a Trifocal IOL: A Systematic Literature Review and Meta-Analysis

    Dec 1, 2022, 00:00

  • PCR102 Development of Conceptual Frameworks and PRO Measures in Ornithine Transcarbamylase Deficiency

    Dec 1, 2022, 00:00

  • RWD101 Impact of COVID-19 Vaccination in Reducing Standard Hospitalization Cost Among COVID-19 Patients in the US – A Retrospective Study

    Dec 1, 2022, 00:00

  • EE144 APAP and Telemonitoring for Initiation and Follow-up of OSA Therapy in Germany: Economic and Environmental Evaluation

    Dec 1, 2022, 00:00

  • MT36 Use of Mobile Health (MHEALTH) Applications in Cancer: A Trend Analysis

    Dec 1, 2022, 00:00

  • EE128 Facing the Challenge of Ageing: Cost-Effectiveness of the SPRINT-T Protocol

    Dec 1, 2022, 00:00

  • HTA40 Did You Just Get a NICE Increase in Price Potential? Severity Multipliers and Price Potential in England

    Dec 1, 2022, 00:00

  • EE176 Cost-Utility Analysis of Fentanyl Sublingual Formulation in the Treatment of Breakthrough Pain in Adults With Cancer, Already on Opioid Maintenance Therapy for Chronic Cancer Pain in Italy

    Dec 1, 2022, 00:00

  • HSD110 Risk Estimation and Risk Prediction of Unmet Healthcare Needs of Disaster Victims Using Machine Learning

    Dec 1, 2022, 00:00

  • RWD122 Strengthening the Patient Voice in Health Outcome Measurement in Real-World Data in Europe – The Health Outcomes Observatory

    Dec 1, 2022, 00:00

  • HSD60 TRENDSTM Knowledge and Attitudes of Pharmacists Regarding Infectious Diseases and Antimicrobial Resistance in Hungary: Questionnaire-Development, Validation and a Quantitative, Cross-Sectional Study

    Dec 1, 2022, 00:00

  • HPR81 Evaluation of the Hungarian Generic Program Between 2010 and 2021

    Dec 1, 2022, 00:00

  • EE468 Healthcare Resource Utilisation and Costs Associated With the Management of Hospitalised COVID-19 Patients in England

    Dec 1, 2022, 00:00

  • HSD16 PCSK-9 Inhibitors for the Control of Hypercholesterolemia: Eligibility for Treatment, Prescription Appropriateness and Outcomes, in a Real-World Clinical Setting

    Dec 1, 2022, 00:00

  • PCR270 Disparities in Mammography Screening: Motivations of Individuals or Structural Racism?

    Dec 1, 2022, 00:00

  • EE207 Real-World Analysis of Adherence, Outcomes and Healthcare Costs of Patients Under Quadruple Combination of Antihypertensives in Italy

    Dec 1, 2022, 00:00

  • EE208 Direct Cost and Indirect Cost of Ischemic Stroke in China

    Dec 1, 2022, 00:00

  • EE80 The Potential Clinical and Economic Benefits of a Next Generation Omicron-Containing (BA.1) Bivalent Sars-Cov-2 Booster Compared to First Generation Prototype Boosters in Germany Assuming BA.4/BA.5 Dominance

    Dec 1, 2022, 00:00

  • SA49 Long-Term Follow-Up of Patients Treated With Cell and Gene Therapy: Scientific and Operational Challenges

    Dec 1, 2022, 00:00

  • HSD20 Real-World Treatment Patterns and Outcomes After Introduction of Immune Checkpoint Inhibitors (ICIs) in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer (aNSCLC) in Europe (EU4+UK)

    Dec 1, 2022, 00:00

  • SA56 A Targeted Literature Review Exploring Surrogacy Relationships Between Estimated Glomerular Filtration Rate (EGFR) and Left Ventricular Mass Index (LVMI) in Clinical Events in Fabry Disease

    Dec 1, 2022, 00:00

  • EE495 Cost-Effectiveness Analysis of Adjuvant Atezolizumab Versus Best Supportive Care in the Treatment of Patients With Resectable Early-Stage Non-Small Cell Lung Cancer and PD-L1≥50% Expression

    Dec 1, 2022, 00:00

  • P23 Bayesian Calibration of a Simulation Model of Opioid Use Disorder

    Dec 1, 2022, 00:00

  • RWD40 Persistence and Switching Patterns of Migraine Prophylactic Medications in Canada: A Retrospective Claims Analysis Comparing Adherence and Evaluating the Economic Burden of Illness

    Dec 1, 2022, 00:00

  • HPR61 Cannabis Edibles: Using a Discrete Choice Experiment to Explore Patterns of Purchase Preferences Among Canadians

    Dec 1, 2022, 00:00

  • EE147 Estimating the Causal Effect of Early Use of Erythropoietic Stimulating Agents in Intermediate-1 to Low-Risk MDS Patients: An Application of the Longitudinal Targeted Maximum Likelihood Estimation

    Dec 1, 2022, 00:00

  • HTA195 Analysis of Health Technology Assessment (HTA) Procedures and Outcomes for Orphan Drugs

    Dec 1, 2022, 00:00

  • EPH172 A Longitudinal Study of Epidemiology and Treatment Management of Wilson Disease in France Based on the French National Claims Database SNDS

    Dec 1, 2022, 00:00

  • EE645 The Effect of Opioid Use on Sick Leave Among Patients With Osteoarthritis Undergoing Joint Replacement: A Propensity Score Adjustment Approach

    Dec 1, 2022, 00:00

  • EE209 Cost-Effectiveness Analysis of Atezolizumab as Adjuvant Treatment in Adult Patients Following Complete Resection and Platinum-Based Chemotherapy with Non-Small Cell Lung Cancer (NSCLC) in Finland

    Dec 1, 2022, 00:00

  • CO152 Clinical Predictors of Axicabtagene Ciloleucel (AXI-CEL) Therapy for Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): A Systematic Literature Review (SLR) and Meta-Analysis

    Dec 1, 2022, 00:00

  • HPR139 Analysis of Public Health Insurance Expenditures in Turkiye Between 2019-2021

    Dec 1, 2022, 00:00

  • HPR77 Variables Impacting Drugs Average Prices in Italy in 2016 - 2021 Period

    Dec 1, 2022, 00:00

  • EE274 Orphan Drug Pricing Comparisons in Low-, Middle- and High-Income Countries

    Dec 1, 2022, 00:00

  • HTA159 Inconsistencies in Measurement of Health-Related Quality of Life (HRQoL)/ Patient-Reported Outcomes (PROs) in Rare Skin Diseases (RSDs)

    Dec 1, 2022, 00:00

  • MSR125 Bias Adjusting for Unmeasured Confounders in Synthetic Control Analysis (SCA) Estimates of Immunotherapy Effectiveness in Advanced Non-Small Cell Lung Cancer (ANSCLC): An Output From the Q-Basel Study

    Dec 1, 2022, 00:00

  • CO154 Differences in Clinical Utility Between Thermocool SmartTouch® Surround Flow Catheter and Smarttouch or Surround Flow Catheter for Arial Fibrillation Ablation: A Systematic Literature Review and Meta-Analysis

    Dec 1, 2022, 00:00

  • P36 Can Real-World Evidence (RWE) Drive European, UK, and US Payer Decisions in the Reassessment of Oncology Therapies?

    Dec 1, 2022, 00:00

  • PCR187 Assessing Treatment Needs and Outcomes in Patients With Parkinson’s Disease: Results From a Real-World Study

    Dec 1, 2022, 00:00

  • SA36 Is Progression-Free Survival a Good Indicator of Overall Survival for Pazopanib in Patients With Synovial Sarcoma?

    Dec 1, 2022, 00:00

  • PCR209 Burden of Chronic Inducible Urticaria Relative to Psoriasis and Atopic Dermatitis in Five European Countries (France, Germany, Italy, Spain, and United Kingdom)

    Dec 1, 2022, 00:00

  • MT22 Qualitative Content Analysis of Secondary Digital Health Terms – Are They Sufficient for Health Outcomes Research Purposes?

    Dec 1, 2022, 00:00

  • HPR50 Challenges That EUnetHTA21 Will Have to Address to Make a Success of Joint Clinical Assessments

    Dec 1, 2022, 00:00

  • HPR82 Price Leakage Due to International Reference Pricing: Impact of Pfizer's Not-for-Profit Pricing Initiative on Price Levels in Additional Countries

    Dec 1, 2022, 00:00

  • EE368 A Three Years Budget Impact Analysis of Hemanext in Italy

    Dec 1, 2022, 00:00

  • EE522 Budget Impact Model of Anti-Obesity Drugs and Bariatric Surgery in People With Obesity in South Korea

    Dec 1, 2022, 00:00

  • HSD33 Good Adherence to Pay-for-Performance and Continuity of Care Reduced Occurrence of Surgery-Needed Diabetic Retinopathy: A Population-Based Cohort Study of 4 Years

    Dec 1, 2022, 00:00

  • EE288 Economic Evaluation of Generic Tacrolimus and Innovator in Renal Transplant Recipients in Egypt

    Dec 1, 2022, 00:00

  • HTA71 Will the New EU HTA Regulations Increase the Methodological Requirements to Conducting Systematic Literature Reviews of Clinical Evidence?

    Dec 1, 2022, 00:00

  • CO36 Safety and Efficacy of Augmentation Therapy in Patients with Alpha-1-Antitrypsin Deficiency: A Systematic Review and Meta-Analysis

    Dec 1, 2022, 00:00

  • HPR31 Analysis of the Difference Between Tender and Reimbursement Prices of Cardiovascular Surgery Medical Devices in Turkiye Between 2017-2021

    Dec 1, 2022, 00:00

  • EPH75 Applying Machine Learning (ML) to Estimate Prevalence of Facioscapulohumeral Muscular Dystrophy (FSHD) and Related Disease Burden: Findings From United States Claims Analysis

    Dec 1, 2022, 00:00

  • EE48 Can We Afford to Overlook the Cost of Avoidable Complications in Type 2 Diabetes: A Health Economic Analysis to Evaluate What Is the ‘Cost of Not’ Acting in Turkey?

    Dec 1, 2022, 00:00

  • HTA261 Comparison of Molecular Tests for Detection of NTRK Gene Fusions in Patients With Advanced Solid Tumours- A Systematic Review and Economic Evaluation

    Dec 1, 2022, 00:00

  • EPH37 High Cardiovascular Disease Risk and Low Lipid-Lowering Treatment in Heterozygous Familial Hypercholesterolemia Patients: A French Nationwide Registry

    Dec 1, 2022, 00:00

  • EE250 An Update of Systematic Review of Cost-Utility Studies Conducted From an Indian Perspective

    Dec 1, 2022, 00:00

  • HPR7 Out-of-Pocket Health Expenditures of Households With Rare Diseases in Turkiye

    Dec 1, 2022, 00:00

  • HPR123 CEE: Brief Overview of Orphan Drug Reimbursement and Selected Clinical Characteristics

    Dec 1, 2022, 00:00

  • MSR130 Comparison of Software for Bayesian Network Meta-Analysis: A Case Study of Binomial Outcomes in Ulcerative Colitis

    Dec 1, 2022, 00:00

  • SA33 Demographic Characteristics of Patients Initiating Topical Combination Therapies for Plaque Psoriasis in Canada: A Claims-Based Analysis

    Dec 1, 2022, 00:00

  • EE122 Estimating Hospital Care Costs Associated With Excess Physical Comorbidities in Patients With Mental Health Disorders in Europe

    Dec 1, 2022, 00:00

  • EE432 Budget Impact Analysis of Avelumab + Best Supportive Care (BSC) as First-Line Maintenance Treatment in Patients With Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) in Ireland

    Dec 1, 2022, 00:00

  • EE4 Hospital Care of Endometriosis in Spain: A Retrospective Multicenter Analysis of Patient Characteristics and Costs

    Dec 1, 2022, 00:00

  • SA2 Use of Systematic Literature Reviews (SLRs) and Meta-Analyses (MA) to Support HTA Submissions: An Application in Pancreatic Cancer

    Dec 1, 2022, 00:00

  • P35 Real-World Evidence of Incidence, Initial Treatment, and Survival of Female Breast Cancer in Germany

    Dec 1, 2022, 00:00

  • EE582 The Principles of the Economic Evaluation and Public Health Committee (CEESP) Doctrine at the French National Authority for Health (HAS)

    Dec 1, 2022, 00:00

  • EPH200 Prevalence and Treatment Patterns of Generalized Pustular Psoriasis (GPP) in Germany – Results of a Delphi Consensus Study

    Dec 1, 2022, 00:00

  • EPH81 The Productivity Burden of Sleep Apnoea in Australia Over a Lifetime: A Modelling Study

    Dec 1, 2022, 00:00

  • PCR125 Censoring in the Time Trade-Off Valuation of Worse-Than-Dead EQ-5D-5L Health States: Can a Willingness-to-Accept Question be the Solution?

    Dec 1, 2022, 00:00

  • HTA65 Socio-Economic Determinants of Health Status During COVID-19 Pandemic in Hungary

    Dec 1, 2022, 00:00

  • EPH164 Estimation of the Burden of C.Difficile Infection in Community and Hospital Settings in France From 2015-2019: Results From a National Health Insurance Database Study (The CLODICIA SNDS Study)

    Dec 1, 2022, 00:00

  • EE293 Challenges for Economic Evaluations of Advanced Therapy Medicinal Products: A Systematic Review

    Dec 1, 2022, 00:00

  • MSR101 Predicting Overall Survival of Immune-Checkpoint Inhibitors (ICIS): Which Distributions Are the Most Accurate? A Systematic Literature Review and Extrapolations of French Cost-Effectiveness Report Assessments

    Dec 1, 2022, 00:00

  • EE444 Еconomic Evaluation of Medical Activity on Fractional Flow Reserve Measurement (FFR) for Functional Assessment of Epicardial Stenoses in Patients With Stable Coronary Heart Disease

    Dec 1, 2022, 00:00

  • RWD125 Demographics and Healthcare Resource Utilization of Patients With Sports-Related Mild Traumatic Brain Injury (SR-MTBI) in the US

    Dec 1, 2022, 00:00

  • CO70 Investigation of Autoimmune Disease With Eosinophilic Esophagitis: A Nationwide Longitudinal Study

    Dec 1, 2022, 00:00

  • HSD88 Female Pharmacy Student's Intention to Work in Community Pharmacy in Saudi Arabia: Using the Theory of Planned Behavior

    Dec 1, 2022, 00:00

  • EE532 Health Impact Projection of Anti-PD-(L)1 Inhibitors in 13 Cancers Indications in France

    Dec 1, 2022, 00:00

  • EE460 A Systematic Review of the Methodological Aspects of Applied Economic Evaluations in the Palliative and End-of-Life Care Settings

    Dec 1, 2022, 00:00

  • EE85 Cost-Effectiveness Analysis of GAAD Algorithm on the Detection of Early-Stage Hepatocellular Carcinoma in Patients With Chronic Liver Disease in China

    Dec 1, 2022, 00:00

  • EE244 Cost of nAMD Management in 3R Level Hospitals in Spain. Comparison of Unitary Cost System vs National Cost Database

    Dec 1, 2022, 00:00

  • HSD97 Automated Versus Manual Prior Authorization for Type 2 Diabetes Mellitus Drugs: A Retrospective Study From Israel

    Dec 1, 2022, 00:00

  • CO102 Systematic Review and Meta-Analysis of Randomized Trials: Efficacy, Immunogenicity, and Safety of Denvax Vaccine

    Dec 1, 2022, 00:00

  • EPH189 Assessing Changes in the Number and Profile of New Cases of Bacterial Sexually Transmitted Infections From 2018-2021: A Descriptive Analysis of German Claims Data

    Dec 1, 2022, 00:00

  • PCR104 The Risk of Developing Diabetes and Impaired Health-Related Quality of Life in Indonesia

    Dec 1, 2022, 00:00

  • HPR42 A New Organizational Model to Manage Chronic Diseases With Digital Medicine Tools

    Dec 1, 2022, 00:00

  • CO76 Value of Axicabtagene Ciloleucel Versus Chemotherapy in the Large B-Cell Lymphoma Treatment: Health Outcomes Based on the Number of Patients Treated in Spain

    Dec 1, 2022, 00:00

  • RWD151 Treatment Satisfaction of Guselkumab for Plaque Psoriasis Patients in a Multi-National, Real-World Setting

    Dec 1, 2022, 00:00

  • EE74 Costing for Socioeconomic Impact Analysis: Implications of Adopting a Patient's Perspective

    Dec 1, 2022, 00:00

  • EE44 Pain Therapy With Spinal Cord Stimulation (SCS) in Patients With Painful Diabetic Neuropathy (PDN): Results of a Budget Impact Model

    Dec 1, 2022, 00:00

  • MSR37 Meaningful Difference in Performance (MDP): A Proposed Method to Improve Evaluation of Meaningful Variation Healthcare Quality Measures

    Dec 1, 2022, 00:00

  • HTA147 Advanced Therapy Medicinal Products (ATMPS) Market Access Challenges in France

    Dec 1, 2022, 00:00

  • EE234 Comparing the Public Health Impact of a 15- or 20-Valent Pneumococcal Conjugate Vaccine Pediatric National Immunization Program in Spain

    Dec 1, 2022, 00:00

  • HPR145 Factors of Access to the Market of Innovative Specialties in Algeria: The Case of Hospital Drugs

    Dec 1, 2022, 00:00

  • EE488 How Is Real-World Data Used in Health Technology Assessments to Inform Reimbursement Decisions for Multiple Sclerosis Drugs? A European Perspective

    Dec 1, 2022, 00:00

  • EE371 Disease Management Costs for Patients With Intermediate-High or High-Risk Renal Cell Carcinoma (RCC) Following Nephrectomy

    Dec 1, 2022, 00:00

  • HTA84 Real-World Assessment of Orphan Drugs via the New Joint Clinical Assessment Route in Europe

    Dec 1, 2022, 00:00

  • EPH24 The Impact of COVID-19 Pandemic on Paediatric Vaccination Coverage Rates

    Dec 1, 2022, 00:00

  • HTA150 RWE in HTA Recommendations for Decision Making: Analysis From Ukrainian Perspective

    Dec 1, 2022, 00:00

  • MSR102 Variance-Bias Trade-Off in Covariate Adjustment in the Context of Synthetic Control Methods

    Dec 1, 2022, 00:00

  • EE569 Axicabtagene Ciloleucel for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the Irish Healthcare Setting: Cost-Utility and Value of Information Analysis

    Dec 1, 2022, 00:00

  • PCR199 Time to First Deterioration in Health-Related Quality of Life (HRQOL) Remains the Most Common Time to Deterioration (TTD) in Non-Small Lung Cancer (NSCLC) Trials

    Dec 1, 2022, 00:00

  • SA38 Mortality Estimates in Patients With Anti-Aquaporin-4 Autoantibody Positive Neuromyelitis Optica Spectrum Disorder

    Dec 1, 2022, 00:00

  • EPH82 Pharmacotherapy of Obesity in the Russian Federation: Pharmacoepidemiological Study

    Dec 1, 2022, 00:00

  • EE427 Annual Cost Savings From the Use of Empagliflozin Over DPP4I in Select Asia-Pacific Countries – Estimates Based on the Emprise East Asia Study

    Dec 1, 2022, 00:00

  • HPR57 Do Favourable Access Conditions and Policies for Biosimilars Result in Increased Consumption in the EU4 and the UK?

    Dec 1, 2022, 00:00

  • MSR34 Forecasting the Long-Term Treatment Effect Duration of Immuno-Oncology Therapies: An Analysis of the Predictive Accuracy of Treatment Waning Methods Applied to Pembrolizumab in Non-Small Cell Lung Cancer

    Dec 1, 2022, 00:00

  • HTA109 Diagnostic Accuracy of 0.3T MRI for Knee Injuries- A Systematic Review

    Dec 1, 2022, 00:00

  • EE536 Patterns of Author Collaboration in Published Cost-Effectiveness Analyses

    Dec 1, 2022, 00:00

  • HSD63 Characteristics and Treatment Patterns of Patients Initiating Cladribine Tablets: A U.S. Commercial and Medicare Advantage Prescription Drug Claims Analysis

    Dec 1, 2022, 00:00

  • HPR105 Examining Attributes of Retailers That Influence Where Cannabis Is Purchased

    Dec 1, 2022, 00:00

  • EE77 Cost-Effectiveness Analysis of Pharmacogenetic-Guided Treatment in Drug Resistant Depression

    Dec 1, 2022, 00:00

  • MSR6 Data-Driven Choice Models for Moral Choice Analysis: Helpful or Harmful?

    Dec 1, 2022, 00:00

  • RWD77 Validation of Prevalence and Incidence Rates for Six Different Diseases Using Livingstone: An Online, Automated Analytical Platform

    Dec 1, 2022, 00:00

  • EPH43 Association Between Human Papillomavirus Vaccination and Serious Adverse Events in Females Aged 9 to 26 Years: A Systematic Review and Meta Analysis

    Dec 1, 2022, 00:00

  • RWD92 Persistence and Patterns of Exposure to Omalizumab in Patients With Asthma in France Between 2009 and 2019 (SOLAIR Study)

    Dec 1, 2022, 00:00

  • PCR164 Assessment of Drug Consumption Habits, Health Behaviour, and Illness Experience of the Adult Population Among Patients With Hypertension

    Dec 1, 2022, 00:00

  • EE73 The Challenge of Demonstrating Cost Effectiveness in Alzheimer's Disease in England: Case Study of a Hypothetical Emerging Treatment

    Dec 1, 2022, 00:00

  • P30 Incorporating Beliefs on the Relevance of Values Into Meta-Analyses of Health State Utility Values Using the Bayesian Power Prior

    Dec 1, 2022, 00:00

  • EE204 Cost-Effectiveness of Everolimus Combination Therapy in Patients After Liver Transplantation Focusing on Cancer Risk: A Markov Model Using Real-World Data

    Dec 1, 2022, 00:00

  • HTA36 Value of Real-World Evidence for Treatments for Ultra Orphan or Rare Diseases: Lessons and Insights From Review of NICE Highly Specialized Technology Assessment Reports (2016-2022)

    Dec 1, 2022, 00:00

  • EE312 Are Methods Used to Generate Utility Values Adequately Included in Technology Assessments for Children and Adolescents? Lessons From HAS Assessments of Manufacturers’ Cost-Utility Analyses

    Dec 1, 2022, 00:00

  • EE585 Human Capital Loss Associated With Ill-Health: Evidence from Patients With End-Stage Kidney Disease in Taiwan

    Dec 1, 2022, 00:00

  • HTA236 Early Diagnosis of Breast Cancer Saved Loss of Employment and Productivity for Women: Real World Evidence of Lifetime Impact

    Dec 1, 2022, 00:00

  • P60 Use Cases for Artificial Intelligence and Machine Learning Methods to Support Health Technology Assessment

    Dec 1, 2022, 00:00

  • RWD133 Assessing the Impact of Bisphosphonates and Selective Estrogen Receptor Modulators in Post-Menopausal Osteoporosis

    Dec 1, 2022, 00:00

  • EE552 Slovenian EQ-5D-5L Value Set

    Dec 1, 2022, 00:00

  • PCR16 Variables Associated With Carer Quality of Life in England Using a Large, National Data Set

    Dec 1, 2022, 00:00

  • MSR106 Towards an Artificial Intelligence-Enabled Social Media Listening Solution to Inform Early Patient-Focused Drug Development Strategies

    Dec 1, 2022, 00:00

  • CO127 Empirical vs Documented Use of Ceftolozane-Tazobactam for the Treatment of Complicated Infections in French Hospital Settings

    Dec 1, 2022, 00:00

  • HPR133 Impact of International Reference Pricing (IRP) on Medicines Reimbursement Prices in Bosnia and Herzegovina

    Dec 1, 2022, 00:00

  • EE156 Public Health Impact and Cost-Effectiveness of Empagliflozin (JARDIANCE®) in the Treatment of Patients with Heart Failure (HF) with Preserved Ejection Fraction (HFPEF) in France, Based on Emperor-Preserved Clinical Trial

    Dec 1, 2022, 00:00

  • HTA155 The Use of Patient Reported Outcomes in Aiding the Reimbursement Decisions of Advanced Medicinal Therapy Products

    Dec 1, 2022, 00:00

  • EE161 Loss of Employment Duration and Productivity for Patients With Different Subtypes and Stages of Lung Cancer

    Dec 1, 2022, 00:00

  • EE504 The Economic Burden of Migraine in Spain: A Nationwide Cost-of-Illness Approach From the Year 2020 European Health Survey in Spain

    Dec 1, 2022, 00:00

  • EE554 Costs Comparison Between Dupilumab and Omalizumab in the Treatment of Severe Allergic Asthma in the Brazilian Private Healthcare Perspective

    Dec 1, 2022, 00:00

  • PCR251 Retrospective Social Listening Study of Patients Living with Systemic Lupus Erythematosus (SLE): Understanding the Patient Experience

    Dec 1, 2022, 00:00

  • HTA145 Living Network Meta-Analysis for Up-to-Date Comparative Effectiveness: A Case Study in Multiple Myeloma Maintenance

    Dec 1, 2022, 00:00

  • MSR68 Development of a Checklist for Studies Reporting the Elicitation of Stated Preferences Values for Child Health Related Quality of Life

    Dec 1, 2022, 00:00

  • PCR258 Citizens’ Preferences for Robot-Assisted Hip Replacement: Results of an Online Cross-Sectional Study in Hungary

    Dec 1, 2022, 00:00

  • EE241 Health Economic Model for Estimating the Cost Impact of Optimized Peripheral Intravascular Catheter Insertion and Post-Insertion Catheter Care

    Dec 1, 2022, 00:00

  • EE539 Social and Economic Burden of HIV in Russia

    Dec 1, 2022, 00:00

  • PCR43 Comparison of Face-to-Face and Online Surveys of Measuring Utility for Metastatic Pancreatic Cancer in Japan Using Composite Time Trade-Off

    Dec 1, 2022, 00:00

  • HTA112 A Pragmatic Payer-Patient Engagement Framework (PPEF) to Support Ethical Formulary Decision Making Process in Rare Disease (RD) Arena in Commercial Payer Settings in the U.S.

    Dec 1, 2022, 00:00

  • HPR143 Why It Is So Difficult to Calculate Bundled Payments? Learnings From a Practical Case in Germany

    Dec 1, 2022, 00:00

  • HTA224 Commissioning Through Evaluation: RWE for Rituximab in the Management of Idiopathic Membranous Nephropathy

    Dec 1, 2022, 00:00

  • PCR60 Self-Reported Impact of Osteogenesis Imperfecta (OI) on Quality of Life (QOL) Domains in Adults

    Dec 1, 2022, 00:00

  • HSD18 Access to Healthcare Services During COVID-19 Restrictions in Kazakhstan: A Nationwide Survey on COVID-19 and Lifestyle Changes

    Dec 1, 2022, 00:00

  • EE384 A Targeted Literature Review of Health State Utility Values in Neuromyelitis Optica Spectrum Disorder

    Dec 1, 2022, 00:00

  • PCR282 Despite the Growing Weight of Patient Voice in Medical Research, Only Few Medical Journals Allow and/or Require Plain Language Summaries (PLS)

    Dec 1, 2022, 00:00

  • EE574 Cemiplimab and Pembrolizumab for Advanced Non-Small Cell Lung Cancer With PD-L1 ≥ 50%: Number Needed to Treat and Cost of Preventing an Event in the Brazilian Private Healthcare System Perspective

    Dec 1, 2022, 00:00

  • PCR182 Validity and Responsiveness of EQ-5D-Y in Children With Haematological Malignancies and Their Caregivers

    Dec 1, 2022, 00:00

  • HPR112 The Average Monthly Income of Full-Time Doctors Working in Hospitals by Type of Healthcare Institution in Hungary

    Dec 1, 2022, 00:00
  • «
  • 21
  • 22
  • 23
  • 24 (current)
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • »